The objective of this study was to determine if plasma CCN2 is associated with abdominal aorta aneurysm (AAA), and future need for AAA repair, and further to assess the potential clinical value of CCN2 in predicting disease outcome. CCN2 was quantified in plasma samples obtained from a cohort of 679 men aged 65-74 at initial ultrasound screening for AAA in the Viborg Vascular (VIVA) screening trial. Plasma CCN2 was correlated with need for future surgical repair in the whole study population (HR = 1.457 (1.081-1.962), p = .013) and in the AAA group alone (HR = 1.431 (1.064-1.926), p = .018), yet the predictive value (CCN2 > 0 and <0 of 0.52 and 0.55, respectively) disqualified its use in clinically relevant AAA repair prediction. In conclusion, CCN2 is independently related to subsequent need for AAA repair, but has negligible predictive power for clinical use.

中文翻译：

---

血浆CCN2与后续腹主动脉瘤修复的需要独立相关。

这项研究的目的是确定血浆CCN2是否与腹主动脉瘤（AAA）有关，以及将来需要进行AAA修复，并进一步评估CCN2在预测疾病结局方面的潜在临床价值。在Viborg血管（VIVA）筛查试验中，在AAA的初次超声筛查中，对来自679名65-74岁男性队列的血浆样本中的CCN2进行了定量。血浆CCN2与整个研究人群（HR = 1.457（1.081-1.962），p = .013）和仅AAA组（HR = 1.431（1.064-1.926），p = .018 ），但预测值（分别为CCN2> 0和<0分别为0.52和0.55）取消了其在临床上相关的AAA修复预测中的使用资格。总之，CCN2与随后的AAA维修需求独立相关，